Raymond James & Associates Vaxart, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding VXRT
# of Institutions
104Shares Held
23.1MCall Options Held
66.1KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA10.4MShares$3.54 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$790,9660.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$603,2770.0% of portfolio
-
Marshall Wace, LLP London, X01.76MShares$599,7190.0% of portfolio
-
State Street Corp Boston, MA851KShares$289,3800.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $43M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...